ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,996.66
1.00%
Dow Jones
43,487.83
0.78%
US Dollar vs MXN
20.55394
-1.17%
Brent Oil
79.055
-1.45%
Bitcoin
104,734.96
1.57%
Pepperstone
Advertisement
Registration Strip Icon for discussion Regístrate para interactuar en nuestros foros activos para discutir con inversores de ideas afines.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. Vistagen Therapeutics Inc (VTGN)

  7. Vistagen Therapeutics Inc (VTGN) Noticias

VTGN

Vistagen Therapeutics (VTGN)

Vistagen Therapeutics Inc
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NASDAQ:VTGN
FechaHoraFuenteTítuloSímboloCompañía
14/01/202516:16Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:VTGNVistagen Therapeutics Inc
14/01/202507:30Business WireVistagen Announces Positive Results from Exploratory Phase 2A Study of PH284 in Cancer CachexiaNASDAQ:VTGNVistagen Therapeutics Inc
13/01/202516:40Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VTGNVistagen Therapeutics Inc
10/01/202507:30Business WireVistagen Initiates Fasedienol Repeat Dose Study for the Acute Treatment of Social Anxiety DisorderNASDAQ:VTGNVistagen Therapeutics Inc
14/11/202415:53Edgar (US Regulatory)Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:VTGNVistagen Therapeutics Inc
14/11/202415:19Edgar (US Regulatory)Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:VTGNVistagen Therapeutics Inc
14/11/202407:30Business WireVistagen to Present at the Stifel 2024 Healthcare ConferenceNASDAQ:VTGNVistagen Therapeutics Inc
07/11/202415:34Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:VTGNVistagen Therapeutics Inc
07/11/202415:20Business WireVistagen Reports Fiscal Year 2025 Second Quarter Financial Results and Corporate UpdateNASDAQ:VTGNVistagen Therapeutics Inc
05/11/202407:30Business WireVistagen to Present at the 2024 Neuroscience Education Institute CongressNASDAQ:VTGNVistagen Therapeutics Inc
01/11/202407:30Business WireVistagen to Report Fiscal Year 2025 Second Quarter Results and Host Corporate Update Conference Call on November 7, 2024NASDAQ:VTGNVistagen Therapeutics Inc
09/10/202407:30Business WireVistagen, The Goldie Hawn Foundation, and MindUP Students to Ring Nasdaq Closing Bell on World Mental Health DayNASDAQ:VTGNVistagen Therapeutics Inc
23/09/202407:30Business WireVistagen Initiates PALISADE-4 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety DisorderNASDAQ:VTGNVistagen Therapeutics Inc
13/08/202415:21Business WireVistagen Reports Fiscal Year 2025 First Quarter Financial Results and Corporate UpdateNASDAQ:VTGNVistagen Therapeutics Inc
06/08/202407:30Business WireVistagen to Report Fiscal Year 2025 First Quarter Results and Host Corporate Update Conference Call on August 13, 2024NASDAQ:VTGNVistagen Therapeutics Inc
09/07/202407:30Business WireVistagen Broadens PH80 Global Intellectual Property Portfolio with New Patents for the Treatment of MigraineNASDAQ:VTGNVistagen Therapeutics Inc
27/06/202407:30Business WireVistagen Awarded Mental Health America’s Platinum Bell Seal for Workplace Mental Health for the Second Consecutive YearNASDAQ:VTGNVistagen Therapeutics Inc
11/06/202415:27Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:VTGNVistagen Therapeutics Inc
11/06/202415:20Business WireVistagen Reports Fiscal Year 2024 Financial Results and Provides Corporate UpdateNASDAQ:VTGNVistagen Therapeutics Inc
11/06/202406:07IH Market NewsU.S. Index Futures Fall Ahead of Federal Reserve Policy Meeting, Crude Oil Prices DeclineNASDAQ:VTGNVistagen Therapeutics Inc
07/06/202407:30Business WireVistagen to Report Fiscal Year 2024 Financial Results and Host Corporate Update Conference Call on June 11, 2024NASDAQ:VTGNVistagen Therapeutics Inc
29/05/202407:30Business WireVistagen to Present at the Jefferies Global Healthcare ConferenceNASDAQ:VTGNVistagen Therapeutics Inc
23/05/202407:30Business WireVistagen to Present at the 2024 American Society of Clinical Psychopharmacology (ASCP) ConferenceNASDAQ:VTGNVistagen Therapeutics Inc
07/05/202407:30Business WireVistagen to Present at the 2024 RBC Capital Markets Global Healthcare ConferenceNASDAQ:VTGNVistagen Therapeutics Inc
25/04/202407:30Business WireVistagen Announces Positive Results from Phase 2A Pilot Study of PH15 for Improvement of Psychomotor Impairment Caused by Mental FatigueNASDAQ:VTGNVistagen Therapeutics Inc
09/04/202407:30Business WireVistagen to Present at the 2024 Anxiety and Depression Association (ADAA) ConferenceNASDAQ:VTGNVistagen Therapeutics Inc
01/04/202407:30Business WireVistagen Initiates PALISADE-3 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder Following Positive Results of PALISADE-2NASDAQ:VTGNVistagen Therapeutics Inc
11/03/202407:30Business WireVistagen to Present at Stifel 2024 Virtual CNS DaysNASDAQ:VTGNVistagen Therapeutics Inc
29/02/202423:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:VTGNVistagen Therapeutics Inc
28/02/202407:30Business WireVistagen to Present at TD Cowen 44th Annual Health Care ConferenceNASDAQ:VTGNVistagen Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:VTGN

Su Consulta Reciente

CCOM
US500
US 500
NASDAQ
MSFT
Microsoft
AMEX
XLV
Health Care Select Sector
AMEX
XLF
Financial Select Sector
USOTC
BNPQY
BNP Paribas (QX)
NYSE
VZ
Verizon Communications
NASDAQ
AAPL
Apple
PM
XAUUSD
Gold vs US Dollar
COIN
BTCUSD
Bitcoin
CCOM
OILBRENT
Brent Oil
NASDAQ
QQQ
Invesco QQQ Trust Series 1
NYSE
DIS
Walt Disney
FX
EURMXN
Euro vs MXN
NYSE
BAC
Bank of America
COIN
ADAUSD
Cardano
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

México
Empresa
Negocios
Popular
Obtener la aplicación
App Store
Google Play

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2025 ADVFN PLC - Todos los derechos reservados